Chinese herbal medicine (CHM) has been used in Chinese NSCLC patients treated with EGFR-TKIs for more than 10 years and has demonstrated its efficacy in delaying EGFR-TKI resistance and alleviating adverse effects in a number of clinical trials (Yang et al., 2018; Jiao et al., 2019; Tang et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.